T2 Biosystems, Inc. (TTOO) announced on Friday that it has successfully defended a key patent for its direct-from-whole-blood detection method in the European Union.
In May 2023, an opposition was filed with the European Patent Office (EPO) by bioMerieux and a strawman representing other undisclosed firms against T2 Biosystems' granted European Patent No. 3 443 124. This patent pertains to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample.
"This decision strengthens our confidence in the extensive protection conferred by our IP portfolio for our proprietary direct-from-whole-blood pathogen detection method," said John Sperzel, Chairman and CEO of T2 Biosystems. "Considering the importance and value of our IP portfolio, we plan to continue defending against such challenges and remain confident in our leading position as we advance our technology, commercial platform, and product pipeline."
